Monovalent rotavirus vaccine effectiveness and long-term impact among children <5 years old in Antananarivo, Madagascar, 2010-2022

Vaccine. 2024 Dec 2;42(26):126321. doi: 10.1016/j.vaccine.2024.126321. Epub 2024 Sep 10.

Abstract

Background: Monovalent rotavirus vaccine substantially reduced rotavirus disease burden after introduction (May 2014) in Madagascar. We examined the effectiveness and long-term impact on acute watery diarrhea and rotavirus-related hospitalizations among children <5 years old at two hospitals in Antananarivo, Madagascar (2010-2022).

Methods: We used a test-negative case-control design to estimate monovalent rotavirus vaccine effectiveness (VE) against laboratory-confirmed rotavirus hospitalizations among children age 6-23 months with documented vaccination status adjusted for year of symptom onset, rotavirus season, age group, nutritional status, and clinical severity. To evaluate the impact, we expanded to children age 0-59 months with acute watery diarrhea. First, we used admission logbook data to compare the proportion of all hospitalizations attributed to diarrhea in the pre-vaccine (January 2010-December 2013), transition period (January 2014-December 2014), and post-vaccine (January 2015-December 2022) periods. Second, we used active surveillance data (June 2013-May 2022) to describe rotavirus positivity and detected genotypes by vaccine introduction period and surveillance year (1 June-31 May).

Result: Adjusted VE of at least one dose against hospitalization due to rotavirus diarrhea among children age 6-23 months was 61 % (95 % CI: -39 %-89 %). The annual median proportion of hospitalizations attributed to diarrhea declined from 28 % in the pre-vaccine to 10 % in the post-vaccine period. Rotavirus positivity among hospitalized children age 0-59 months with acute watery diarrhea was substantially higher during the pre-vaccine (59 %) than the post-vaccine (23 %) period. In the pre-vaccine period, G3P[8] (76 %) and G2P[4] (12 %) were the dominant genotypes detected. Although genotypes varied by surveillance year, G1P[8] and G2P[4] represented >50 % of the genotypes detected post-introduction.

Conclusions: Rotavirus vaccine has been successfully implemented in Madagascar's routine childhood immunization program and had a large impact on rotavirus disease burden, supporting continued use of rotavirus vaccines in Madagascar.

Keywords: Genotype; Madagascar; Rotavirus; Rotavirus surveillance; Rotavirus vaccine effectiveness; Rotavirus vaccine impact.

MeSH terms

  • Case-Control Studies
  • Child, Preschool
  • Diarrhea* / epidemiology
  • Diarrhea* / prevention & control
  • Diarrhea* / virology
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Immunization Programs
  • Infant
  • Infant, Newborn
  • Madagascar / epidemiology
  • Male
  • Rotavirus Infections* / epidemiology
  • Rotavirus Infections* / prevention & control
  • Rotavirus Vaccines* / administration & dosage
  • Rotavirus Vaccines* / immunology
  • Rotavirus Vaccines* / therapeutic use
  • Rotavirus* / genetics
  • Rotavirus* / immunology
  • Seasons
  • Vaccination / statistics & numerical data
  • Vaccine Efficacy / statistics & numerical data
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / immunology

Substances

  • Rotavirus Vaccines
  • Vaccines, Attenuated